Electronic Supplementary Material (ESI) for Polymer Chemistry. This journal is © The Royal Society of Chemistry 2024

The Synthesis of Polyisoxazoles Incorporating Fatty Acids: Electronic Supplementary Information.


# Table of Contents

| 1.0                             | Extra                               | a experimental data                                                                                                                                                                                                                                                                                                                                                                                            | 3                                            |
|---------------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| 1.1                             | (1                                  | E,3E)-Isophthalaldehyde dioxime <sup>1</sup>                                                                                                                                                                                                                                                                                                                                                                   | 3                                            |
| 1.2                             | (1                                  | Z,3Z)-N <sup>1</sup> ,N <sup>13</sup> -Dihydroxyisophthalimidoyl dichloride 1a <sup>1</sup>                                                                                                                                                                                                                                                                                                                    | 3                                            |
| 1.3                             | (1                                  | <i>E,4E</i> )-Terephthalaldehyde dioxime <sup>1</sup>                                                                                                                                                                                                                                                                                                                                                          | 3                                            |
| 1.4                             | (1                                  | Z,3Z)-N' <sup>1</sup> ,N' <sup>3</sup> -Dihydroxyterephthalimidoyl dichloride 1b <sup>1</sup>                                                                                                                                                                                                                                                                                                                  | 3                                            |
| 1.5                             | 3,                                  | 4-Diphenyl-1,2,5-oxadiazol-2-oxide 2 <sup>2</sup>                                                                                                                                                                                                                                                                                                                                                              | 4                                            |
| 1.6                             | N                                   | <i>N</i> -Bis(2-hydroxyethyl)acetamide 4a <sup>3</sup>                                                                                                                                                                                                                                                                                                                                                         | 4                                            |
| 1.7                             | G                                   | eneral procedure for the synthesis of diols 4b-f                                                                                                                                                                                                                                                                                                                                                               | 4                                            |
| 1                               | .7.1                                | <i>N,N</i> -Bis(2-hydroxyethyl)palmitamide 4b                                                                                                                                                                                                                                                                                                                                                                  | 5                                            |
| 1                               | .7.2                                | <i>N,N</i> -Bis(2-hydroxyethyl)stearamide 4c <sup>4</sup>                                                                                                                                                                                                                                                                                                                                                      | 5                                            |
| 1                               | .7.3                                | <i>N,N</i> -Bis(2-hydroxyethyl)oleamide 4d <sup>5</sup>                                                                                                                                                                                                                                                                                                                                                        | 5                                            |
| 1                               | 7.4                                 | (9Z,12Z)-N,N-Bis(2-hydroxyethyl)octadeca-9,12-dienamide 4e <sup>5</sup>                                                                                                                                                                                                                                                                                                                                        | 6                                            |
| 1.8                             | (9                                  | <i>Z</i> ,12 <i>Z</i> ,15 <i>Z</i> )- <i>N</i> , <i>N</i> -Bis(2-hydroxyethyl)octadeca-9,12,15-trienamide 4f <sup>5</sup>                                                                                                                                                                                                                                                                                      | 6                                            |
| 1.9                             | Μ                                   | ethyl 8-(4-octyl-3-phenyl-4,5-dihydroisoxazol-5-yl)octanoate and regioisomers 8a-d                                                                                                                                                                                                                                                                                                                             | 7                                            |
| 1.1                             | 0 G                                 | eneral procedure for the synthesis of oligomers O <sup>1</sup> 3, O <sup>1</sup> 5a, O <sup>2</sup> 5a and O <sup>1</sup> 5c(S) Stearic                                                                                                                                                                                                                                                                        | 7                                            |
| 1                               | .10.1                               | O <sup>1</sup> 3-ABA oligomer (3-1a-3)                                                                                                                                                                                                                                                                                                                                                                         | 7                                            |
| 1.10.2                          |                                     | O <sup>1</sup> 5a-ABA oligomer (5a-1a-5a)                                                                                                                                                                                                                                                                                                                                                                      | 8                                            |
| 1                               | .10.3                               | O <sup>2</sup> 5a-ABABA oligomer (5a-1a-5a-1a-5a)                                                                                                                                                                                                                                                                                                                                                              | 8                                            |
| 1                               | .10.4                               | O <sup>1</sup> 5c(S)-ABA oligomer (5c(S)-1a-5c(S))                                                                                                                                                                                                                                                                                                                                                             | 9                                            |
| 2.0                             | NM                                  | R and VT NMR data for new compounds                                                                                                                                                                                                                                                                                                                                                                            | . 10                                         |
| 2.1                             | N                                   | N-di(prop-2-yn-1-yl)acetamide 3                                                                                                                                                                                                                                                                                                                                                                                | . 10                                         |
| 2.2                             | N,                                  | N-bis(2-(prop-2-yn-1-yloxy)ethyl)acetamide 5a(Me)                                                                                                                                                                                                                                                                                                                                                              | 11                                           |
| 2.3                             |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                |                                              |
|                                 | N,                                  | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)                                                                                                                                                                                                                                                                                                                                                             |                                              |
| 2.4                             |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                | 12                                           |
| 2.4<br>2.5                      | N,                                  | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)                                                                                                                                                                                                                                                                                                                                                             | 12<br>13                                     |
|                                 | N,<br>N,                            | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)                                                                                                                                                                                                                                                                                                        | 12<br>13<br>14                               |
| 2.5                             | N,<br>N,<br>(9                      | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)oleamide 5d(O)                                                                                                                                                                                                                                                     | 12<br>13<br>14<br>15                         |
| 2.5<br>2.6                      | N,<br>N,<br>(9<br>(9                | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)oleamide 5d(O)<br>Z,12Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12-dienamide 5e(L)                                                                                                                                                                          | 12<br>13<br>14<br>15<br>16                   |
| 2.5<br>2.6<br>2.7               | N,<br>N,<br>(9<br>(9<br>M           | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)oleamide 5d(O)<br>Z,12Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12-dienamide 5e(L)<br>Z,12Z,15Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12,15-trienamide 5f(Ln)                                                                                      | 12<br>13<br>14<br>15<br>16<br>17             |
| 2.5<br>2.6<br>2.7<br>2.8        | N,<br>N,<br>(9<br>(9<br>M<br>O      | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)oleamide 5d(O)<br>Z,12Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12-dienamide 5e(L)<br>Z,12Z,15Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12,15-trienamide 5f(Ln)<br>ethyl-8-(4-octyl-3-phenyl-4,5-dihydroisoxazol-5-yl)octanoate and regioisomer 8a-d | 12<br>13<br>14<br>15<br>16<br>17<br>19       |
| 2.5<br>2.6<br>2.7<br>2.8<br>2.9 | N,<br>N,<br>(9<br>(9<br>M<br>O<br>O | N-bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)<br>N-bis(2-(prop-2-yn-1-yloxy)ethyl)oleamide 5d(O)<br>Z,12Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12-dienamide 5e(L)<br>Z,12Z,15Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12,15-trienamide 5f(Ln)<br>ethyl-8-(4-octyl-3-phenyl-4,5-dihydroisoxazol-5-yl)octanoate and regioisomer 8a-d | 12<br>13<br>14<br>15<br>16<br>17<br>19<br>20 |

| 2.13 | P(1a-co-5a(Me))                                                                      | 24 |
|------|--------------------------------------------------------------------------------------|----|
| 2.14 | P(1a-co-5b(P)) Palimitic                                                             | 25 |
| 2.15 | P(1a-co-5c(S)) Stearic                                                               | 26 |
| 2.16 | P(1a-co-5d(O)) Oleic                                                                 | 27 |
| 2.17 | P(1a-co-5e(L)) Linoleic                                                              | 29 |
| 2.18 | P(1a-co-5f(Ln)) Linolenic                                                            | 31 |
| 2.19 | P <sub>base</sub> (1a-co-5a(S)) Stearic                                              | 34 |
| 2.20 | P <sub>base</sub> (1b-co-5a(S)) Stearic                                              | 37 |
| 2.21 | 8a-d diastereomer and regioisomeric mixture                                          | 40 |
| 2.22 | 3,4-Diphenyl-1,2,5-oxadiazol-2-oxide 2                                               | 43 |
| 3.0  | Variable Temperature NMR spectra                                                     | 44 |
| 4.0  | Infrared spectra                                                                     | 46 |
| 5.0  | MALDI-TOF mass spectra for selected polymers                                         | 54 |
| 6.0  | DMA data P <sub>base</sub> (1a-co-5c(S)) and P <sub>base</sub> (1b-co-5c(S)) Stearic | 57 |
| 7.0  | Experimental data for screening of base-mediated polymerisations.                    | 57 |
| 8.0  | GPC data of entries 1-15 from section 8.0                                            | 58 |
| 9.0  | Thermal Gravimetric Analysis of all polymers and ABA type oligomers                  | 62 |
| 10.0 | References                                                                           | 63 |

## **1.0** Extra experimental data.

#### 1.1 (1*E*, 3*E*)-Isophthalaldehyde dioxime<sup>1</sup>



Sodium acetate (13.4 g, 164 mmol, 2.2 eq.) and hydroxylamine hydrochloride (11.4 g, 164 mmol, 2.2 eq.) were dissolved in water (50 ml) and added to isophthalaldehyde (10.0 g, 75 mmol, 1 eq.) dispersed in ethanol (50 ml). A white precipitate began to form within 30 minutes. After 4 hours the solid precipitate was

recovered by Buchner filtration and washed with cold ethanol, purification of the precipitate by recrystallisation from EtOAc gave a cream powder. (8.7 g, 71 %); m.p. 186 – 188 °C (lit. 181.2 – 182.0 °C);  $v_{max}$ /cm<sup>-1</sup> 3203 (OH), 2920 (C-H), 2790 (C-H), 1642 (C=N), 1490 (N-O), 945 (C-H); <sup>1</sup>H NMR (400MHz, d6-acetone)  $\delta$  10.46 (s, 2H, OH), 8.17 (s, 2H, HC=N), 7.88 (s, 1H, H<sup>2</sup>), 7.62 (dd, *J* = 7.5, 1.5 Hz, 2H, H<sup>4,6</sup>), 7.42 (t, *J* = 7.5 Hz 1H, H<sup>5</sup>); <sup>13</sup>C (101 MHz, d6-Acetone)  $\delta$  148.97 (C=N), 134.74 (C<sup>1,3</sup>), 129.86 (C<sup>5</sup>), 128.25 (C<sup>6,4</sup>), 125.47 (C<sup>2</sup>).


#### 1.2 (1Z,3Z)-N<sup>1</sup>,N<sup>3</sup>-Dihydroxyisophthalimidoyl dichloride 1a<sup>1</sup>

HO\_N\_OH CI\_6\_4\_CI

Isophthalaldehyde dioxime (7.4 g, 45.1 mmol, 1eq.) was dissolved in DMF (50 ml) at RT. *N*-Chlorosuccinimide (13.2 g, 99.2 mmol, 2.2 eq.) was introduced in 5 parts over the course of an hour. Two hours after the last portion was added the reaction

mixture was poured into cold water (150 ml) and extracted with ethyl acetate (150 ml). The organic layer was washed with water (5 × 50 ml) and saturated sodium thiosulfate solution (1 × 50 ml), then dried over MgSO<sub>4</sub>. Solvent removal *in vacuo* gave a crude yellow solid, which was purified by recrystallization from toluene to give a cream solid, (8.8 g, 84 %); m.p. 159 – 161 °C (lit. 155.7 – 156.0 °C)  $v_{max}/cm^{-1}$  3265 (OH), 1624 (C=N), 1483 (N-O), 990 (C-H), 802 (C-Cl); <sup>1</sup>H NMR (500MHz, Acetone) 11.58 (s, 2H, OH), 8.35 (s, 1H, H<sup>2</sup>), 7.96 (dd, *J* = 8.0, 1.5 Hz, 2H, H<sup>4,6</sup>), 7.57 (t, *J* = 8.0 Hz, 1H, H<sup>5</sup>); <sup>13</sup>C NMR (126 MHz, Acetone)  $\delta$  136.90 (C=N), 134.45 (C<sup>1,3</sup>), 129.93 (C<sup>5</sup>), 129.37 (C<sup>4,6</sup>), 125.82 (C<sup>2</sup>).


#### 1.3 (1*E*,4*E*)-Terephthalaldehyde dioxime<sup>1</sup>



Sodium acetate (13.4 g, 164 mmol, 2.2 eq.) and hydroxylamine hydrochloride (11.4 g, 164 mmol, 2.2 eq.) were dissolved in water (50 ml) and added to isophthalaldehyde (10.0 g, 75 mol, 1 eq.) dispersed in ethanol (50 ml). A white precipitate began to form within 30 minutes. After 4 hours the solid precipitate was

recovered by Buchner filtration and washed with cold ethanol, purification of the precipitate by recrystallisation from EtOAc gave a pure white solid, (9.3 g, 76 %); m.p. 176 – 178 °C (lit. 181.2 – 182.0 °C);  $v_{max}$ /cm<sup>-1</sup> 3137 (OH), 2983 (C-H), 1624 (C=N); <sup>1</sup>H NMR (400MHz, d6-acetone)  $\delta$  10.44 (s, 2H, OH), 8.15 (s, 2H, HC=N), 7.65 (s, 4H, H<sup>2,3,5,6</sup>); <sup>13</sup>C (101 MHz, d6-Acetone)  $\delta$  148.98 (C=N), 135.14 (C<sup>1,3</sup>), 127.71 (C<sup>2,3,5,6</sup>).


1.4 (1Z,3Z)-N<sup>1</sup>,N<sup>3</sup>-Dihydroxyterephthalimidoyl dichloride 1b<sup>1</sup>



Terephthalaldehyde dioxime (8.7 g, 53 mmol, 1 eq.) was dissolved in DMF (50 ml) at RT. *N*-Chlorosuccinimide (14.2 g, 106 mmol, 2.0 eq.) was introduced in 5 parts over the course of an hour. Two hours after the last portion was added the reaction mixture was poured into cold water (150 ml) and extracted with ethyl acetate (150

ml). The organic layer was washed with water (5 × 50 ml) and saturated sodium thiosulfate solution (1 × 50 ml), then dried over MgSO<sub>4</sub>. Solvent removal *in vacuo* gave a crude yellow solid, which was purified by recrystallization from toluene to give a white solid. (9.1 g, 74 %); m.p. 206 –208 °C;  $v_{max}/cm^{-1}$  3260 (OH), 3053 (C-H), 1675 (C=N), 802(C-Cl); <sup>1</sup>H NMR (500MHz, d6-acetone) 11.62 (s, 2H, OH), 7.94 (s, 4H, H<sup>2,3,5,6</sup>); <sup>13</sup>C NMR (126 MHz, d6-acetone)  $\delta$  136.99 (C=N), 135.65 (C<sup>1,4</sup>), 127.83 (C<sup>2,3,5,6</sup>).


#### 1.5 3,4-Diphenyl-1,2,5-oxadiazol-2-oxide 2<sup>2</sup>



A solution of saturated sodium carbonate (5 ml) was added to a solution of benzaldehyde oximoyl chloride (0.26 g, 1.67 mmol) in diethyl ether (10 ml). The mixture was stirred rapidly for 24 h and then transferred to a separating funnel. The organic layer was removed, and the aqueous layer extracted with diethyl ether (2 x

10 ml). The combined organic layers were washed with water (2 x 5 ml) and dried with anhydrous magnesium sulphate. Evaporation of the solvent yielded crude 3,4-diphenyl-1,2,5-oxadiazol-2-oxide 9a (0.13 g, 65 %). Recrystallisation from ethanol gave white needles (0.06 g, 30 %); m.p. 110 – 112 °C;  $v_{max}$  / cm<sup>-1</sup>: 1591 (C=N), 1572 (C=N), 1504, 1441, 1419, 1327; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 – 7.51 (m, 5H, H<sup>cyε</sup>), 7.47 – 7.42 (m, 5H, H<sup>dδe</sup>); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  156.34 (C<sup>α</sup>), 131.10 (C<sup>ε</sup>), 130.66 (C<sup>e</sup>), 129.13 (C<sup>d/δ</sup>), 129.05 (C<sup>d/δ</sup>), 128.78 (C<sup>c</sup>), 128.39 (C<sup>γ</sup>), 126.75 (C<sup>β</sup>), 122.96 (C<sup>b</sup>), 114.38(C<sup>a</sup>); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>14</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub> + Na<sup>+</sup>): 261.0634, found: 261.0636 (M + Na<sup>+</sup>).

#### 1.6 *N,N*-Bis(2-hydroxyethyl)acetamide 4a<sup>3</sup>



Diethanolamine (20.0 g, 19.0 mmol, 1 eq.) was dissolved in THF (150 ml) and cooled to 0  $^{\circ}$ C in an ice bath. Acetic anhydride (23.3 g, 22.8 mmol, 1.2 eq.) was added dropwise (1 drop every two seconds) over the course of 4 hours. The


solution was left to come to room temperature overnight. A sample was taken in the morning and analysed with NMR and MS, revealing a mixture of products. The solution was put under vacuum at 65 °C to remove acetic acid and any residual acetic anhydride. MS/NMR continued to show multiple products, particularly double acetylated impurities. The crude product was taken back into methanol (100 ml) along with K<sub>2</sub>CO<sub>3</sub> (7.00 g, 50.6 mmol) and refluxed for 5 hours. Water was then added until the solution was clear, following this it was neutralised with aqueous HCl (2 M, 80 ml). Methanol and water were removed in vacuo, to leave a yellow oil and solid. The oil was taken into acetone and filtered to remove the solid. The filtrate was then reduced *in vacuo* to leave a yellow oil and some white solid. Under N<sub>2</sub> the yellow oil was taken into dry acetone and dried with 4 Å MS for 1 hour, the solution was then filtered to remove the residual white solid and sieves. The filtrate was once again reduced *in vacuo* to leave a yellow oil. (1.9 g, 69 %); v<sub>max</sub> / cm<sup>-1</sup>: 3353 (OH), 2934 (C-H), 1605 (C=O), 1036 (C-O); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  4.81 (brs, 2H, OH), 3.76 – 3.67 (m, 4H, H<sup>2/2'</sup>), 3.51 – 3.38 (m, 4H, H<sup>1/1'</sup>), 2.09 (s, 3H, CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  173.15 (C=O), 60.84 (C<sup>1/1'</sup>), 60.46 (C<sup>1/1'</sup>), 53.15 (C<sup>2/2'</sup>), 50.34 (C<sup>2/2'</sup>), 22.07 (CH<sub>3</sub>); *m*/z: (ES<sup>+</sup>) 169.5 [MNa]<sup>+</sup>.

#### 1.7 General procedure for the synthesis of diols 4b-f

*N*-methyl morpholine (1.1 eq.) was added to the appropriate fatty acid (1 eq., 0.5 M) in dry  $Et_2O$  for saturated fatty acids or dry THF for unsaturated fatty acids). Ethyl chloroformate (1.1 eq.) was added dropwise and the reaction was stirred for 30 minutes. The precipitate was removed by filtration and the filtrate was added dropwise to diethanolamine (1.1 eq., 0.5M) and triethylamine (1.1 eq., 0.5 M)

in dry DMF at room temperature under N<sub>2</sub>. After 3 hrs the reaction was quenched with 2 M HCl (20 mL) and extracted with Et<sub>2</sub>O (200 mL). The organic layer washed with water (2 x 50 mL) and brine (50 mL), before drying over MgSO<sub>4</sub>. The solvent was removed in vacuo to leave a crude product. Unsaturated amides 4d-f were purified by column chromatography through a silica plug (EtOAc, Rf = 0.2). Saturated amides **4b-c** were purified by recrystallisation from Et<sub>2</sub>O.

1.7.1 *N*,*N*-Bis(2-hydroxyethyl)palmitamide 4b



General procedure for the c, mean k i g e c 0 followed using palmitic acid (12.8 g, 49.9 mmol, 1 eq.), p n followed using palmitic acid (12.8 g, 49.9 mmol, 1 eq.), NMM (5.55 g, 54.9 mmol, 1.1 eq.), ethyl chloroformate (5.96 g, 54.9 mmol, 1.1 eq.), diethanolamine (5.8 g,


54.9 mmol, 1.1 eq.), and TEA (5.6 g, 54.9 mmol, 1.1 eq.) to give a white solid. (9.4 g, 55%); R<sub>f</sub> = 0.2 in 100 % EtOAc; m.p. 60 – 62 °C; v<sub>max</sub>/cm<sup>-1</sup>3317 (O-H), 2916 (C-H), 2849 (C-H), 1611 (C=O); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.90 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 3.79 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 3.57 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.49 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.24 (brs, 2H, H<sup>OH</sup>), 2.39 (t, J = 7.5 Hz, 2H, H<sup>b</sup>), 1.73 – 1.50 (m, 2H, H<sup>c</sup>) 1.37 -1.15 (m, 24H, H<sup>d-o</sup>), 0.88 (t, J = 7.0 Hz, 3H, H<sup>p</sup>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  175.85 (C<sup>a</sup>), 61.52 (C<sup>2/2'</sup>), 61.12 (C<sup>2/2'</sup>), 52.42 (C<sup>1/1'</sup>), 50.77 (C<sup>1/1'</sup>), 33.89 (C<sup>b</sup>), 31.98 (C<sup>n</sup>), 29.87 – 29.23 (C<sup>d-m</sup>), 25.14 (C<sup>c</sup>), 22.74 (C<sup>o</sup>), 14.13 (C<sup>p</sup>); *m*/*z*: (ES<sup>+</sup>) calcd. (C<sub>20</sub>H<sub>41</sub>NO<sub>3</sub> + Na<sup>+</sup>): 366.3, found: 366.1 (M + Na<sup>+</sup>).

1.7.2 *N*,*N*-Bis(2-hydroxyethyl)stearamide 4c<sup>4</sup>

General procedure for the synthesis of diols was followed using stearic acid (30.0 g, 105.4 mmol, 1 eq.), NMM (11.7 g, 116.0 mmol, 1.1 eq.), ethyl chloroformate (12.6 g, 116.0 mmol, 1.1 eq.),

diethanolamine (12.2 g, 116.0 mmol, 1.1 eq.), and TEA (11.7 g, 116.0 mmol, 1.1 eq.) to give a white solid. (25.0, 64 %); R<sub>f</sub> = 0.2 in 100 % EtOAc; m.p. 72 – 75 °C; v<sub>max</sub>/cm<sup>-1</sup> 3409 (O-H) 2918 (C-H), 2849 (C-H), 1616 (C=O); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.86 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.80 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.57 (t, J = 5.0, 2H,  $H^{1/1'}$ ), 3.52 (t, J = 5.0 Hz, 2H,  $H^{1/1'}$ ), 2.40 (t, J = 7.5 Hz, 2H,  $H^{b}$ ), 1.71 – 1.58 (m, 2H, H<sup>c</sup>), 1.40 – 1.19 (m, 28H, H<sup>d-q</sup>), 0.90 (t, J = 7.0 Hz, 3H, H<sup>r</sup>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.92 (C<sup>a</sup>), 61.87 (C<sup>2/2'</sup>), 61.04 (C<sup>2/2'</sup>), 52.35 (C<sup>1/1'</sup>), 50.68 (C<sup>1/1</sup>), 33.78 (C<sup>b</sup>), 32.06 (C<sup>p</sup>), 20.95 – 29.40 (C<sup>d-q</sup>), 25.43 (C<sup>c</sup>), 22.83 (C<sup>q</sup>), 14.13 (C<sup>r</sup>); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>22</sub>H<sub>45</sub>NO<sub>3</sub> + Na<sup>+</sup>): 394.3, found: 394.1 (M + Na<sup>+</sup>).

1.7.3 *N*,*N*-Bis(2-hydroxyethyl)oleamide 4d<sup>5</sup>




chloroformate (12.7 g, 116.8 mmol, 1.1 eq.),

diethanolamine (12.3 g, 116.8 mmol, 1.1 eq.), and TEA (11.4 g, 116.8 mmol, 1.1 eq.) to give a pale yellow oil. (33.7 g, 86 %); R<sub>f</sub> = 0.2 in 100 % EtOAc; v<sub>max</sub>/cm<sup>-1</sup> 3309 (O-H), 3005(=C-H), 2922 (C-H), 2853 (C-H), 1610 (C=O), 1463 (C-H), 1419 (C-N), 756 (=C-H); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.42 – 5.24 (m, 2H, H<sup>i/j</sup>), 4.51 (brs, 2H, H<sup>OH</sup>), 3.79 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.75 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.52 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 3.48 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 2.77 (t, J = 6.5 Hz, H<sup>linoleic</sup>), 2.48 (t, J = 7.5 Hz, 2H, H<sup>b</sup>), 2.07 – 1.94 (m, 4H, H<sup>h/k</sup>), 1.67 – 1.54 (m, 2H, H<sup>c</sup>), 1.38 – 1.21 (m, 20H, H<sup>d-g/l-q</sup>), 0.88 (t, J = 7.0 Hz, 3H, H<sup>r</sup>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.63 (C<sup>a</sup>), 130.21 (C<sup>linoleic</sup>), 130.02 (C<sup>i</sup>), 129.78 (C<sup>j</sup>), 127.92 (C<sup>linoleic</sup>), 61.22 (C<sup>2/2'</sup>), 60.73

(C<sup>2/2'</sup>), 52.31 (C<sup>1/1'</sup>), 50.63 (C<sup>1/1'</sup>), 33.66 (C<sup>b</sup>), 31.95 (C<sup>p</sup>), 30.87 - 29.20 (C<sup>d-g/l-o</sup>), 27.27 (C<sup>h</sup>), 27.25 (C<sup>k</sup>), 25.63 (C<sup>linoleic</sup>), 25.37 (C<sup>c</sup>), 22.72 (C<sup>q</sup>), 14.16 (C<sup>r</sup>); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>22</sub>H<sub>43</sub>NO<sub>3</sub> + Na<sup>+</sup>): 392.3, found: 392.4 (M + Na<sup>+</sup>).

1.7.4 (9Z,12Z)-N,N-Bis(2-hydroxyethyl)octadeca-9,12-dienamide 4e<sup>5</sup>



chloroformate (12.8 g, 117.7 mmol, 1.1 eq.),


diethanolamine (12.4 g, 117.7 mmol, 1.1 eq.), TEA (11.9 g, 117.7 mmol, 1.1 eq.) to give a pale yellow oil, (33.7 g, 78 %, Rf = 0.2 in 100% EtOAc). v<sub>max</sub>/cm<sup>-1</sup>: 3339 (O-H), 3008 (=C-H), 2922 (C-H), 2853 (C-H), 1616 (C=O), 1464 (C-H), 1420 (C-N), 1050 (C-OH), 723 (=C-H);  $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.55 – 5.17 (m, 4H, H<sup>i/j/l/m</sup>), 4.87 (brs, 2H, H<sup>OH</sup>), 3.79 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.76 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.53 (t, J = 4.5 Hz, 2H, H<sup>1/1'</sup>), 3.49 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 2.77 (t, J = 6.5 Hz, 2H, H<sup>k</sup>), 2.39 (t, J = 7.5 Hz, 2H, H<sup>b</sup>), 2.07 - 2.02 (m, 4H, H<sup>h/n</sup>), 1.70 - 1.53 (m, 2H, H<sup>d</sup>), 1.41 - 1.21 (m, 14H, H<sup>c-g/o-q</sup>), 0.89 (t, J = 7.0 Hz, 3H, H<sup>r</sup>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 175.79 (C<sup>a</sup>), 130.20 (C<sup>m</sup>), 130.01 (C<sup>i</sup>), 128.02 (C<sup>j</sup>), 127.90 (C<sup>i</sup>), 61.05 (C<sup>2/2'</sup>), 60.63 (C<sup>2/2'</sup>), 52.31 (C<sup>1/1'</sup>), 50.54 (C<sup>1/1'</sup>), 33.61 (C<sup>b</sup>), 31.52 (C<sup>p</sup>), 29.66 (C<sup>g</sup>), 29.50 (C<sup>o</sup>), 29.45 (C<sup>d</sup>), 29.43 (C<sup>e</sup>), 29.24 (C<sup>f</sup>), 27.23 (C<sup>n</sup>), 27.19 (C<sup>h</sup>), 25.63 (C<sup>k</sup>), 25.33 (C<sup>c</sup>), 22.57 (C<sup>q</sup>), 14.08 (C<sup>r</sup>); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>22</sub>H<sub>41</sub>NO<sub>3</sub> + Na<sup>+</sup>): 390.3, found: 390.4 (M + Na<sup>+</sup>).

#### 1.8 (9Z,12Z,15Z)-N,N-Bis(2-hydroxyethyl)octadeca-9,12,15-trienamide 4f<sup>5</sup>

General procedure for the synthesis of diols was followed using linolenic acid, 70 % (9 g, 32.3 mmol, 1.1 eq.), NMM (3.6 g, 35.6 mmol, 1.1 eq.), ethyl chloroformate (3.9 g, 35.6 mmol, 1.1 eq.),

diethanolamine (3.7 g, 35.6 mmol, 1.1 eq.) and TEA (3.6 g, 35.6 mmol, 1.1 eq.) to give a pale yellow oil. (7.0 g, 59 %); R<sub>f</sub> = 0.2 in 100 % EtOAc; v<sub>max</sub>/cm<sup>-1</sup> 3345(O-H) 2920 (C-H), 2857 (C-H), 1624 (C=O); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.54 – 5.17 (m, 6H, H<sup>i/j/l/m/o/p</sup>), 4.13 (brs, 2H, H<sup>OH</sup>), 3.79 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.74 (t, J = 5.0 Hz, 2H, H<sup>2/2'</sup>), 3.51 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 3.47 (t, J = 5.0 Hz, 2H, H<sup>1/1'</sup>), 2.87 - 2.71 (m, 4H, H<sup>kn</sup>), 2.36 (t, J = 7.5 Hz, 2H, H<sup>b</sup>), 2.14 – 1.94 (m, 4H, H<sup>hq</sup>), 1.75 – 1.49 (m, 2H, H<sup>c</sup>), 1.37 – 1.22 (m, 8H,  $H^{d-g}$ ), 0.95 (t, J = 7.5 Hz, 3H, H<sup>r</sup>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  175.74 (C<sup>a</sup>), 132.04 (C<sup>i/j/l/m/o/p</sup>), 130.35 (C<sup>i/j/l/m/o/p</sup>), 128.37 (C<sup>i/j/l/m/o/p</sup>), 128.33 (C<sup>i/j/l/m/o/p</sup>), 127.80 (C<sup>i/j/l/m/o/p</sup>), 127.20 (C<sup>i/j/l/m/o/p</sup>), 61.46 (C<sup>2/2'</sup>), 60.84 (C<sup>2/2'</sup>), 52.35 (C<sup>1/1'</sup>), 50.68 (C<sup>1/1'</sup>), 33.70 (C<sup>b</sup>), 29.70 (C<sup>g</sup>), 29.51 (C<sup>d</sup>), 29.48 (C<sup>e</sup>), 29.28 (C<sup>f</sup>), 27.31 (C<sup>h</sup>), , 25.70 (C<sup>k</sup>), 25.61 (C<sup>n</sup>), 25.38 (C<sup>c</sup>), 20.63 (C<sup>q</sup>), 14.36 (C<sup>r</sup>); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>22</sub>H<sub>39</sub>NO<sub>3</sub> + Na<sup>+</sup>): 388.3, found: 388.1 (M + Na<sup>+</sup>).

#### 1.9 Methyl 8-(4-octyl-3-phenyl-4,5-dihydroisoxazol-5-yl)octanoate and regioisomers 8a-d




Methyl oleate (0.38 g, 1.3 mmol, 1 eq.) and **1a** (0.20 g, 1.3 mmol, 1 eq.) were dissolved in DMF (0.5 M) at RT, 4Å MS were added and the mixture was stirred for 30 minutes. It was then heated to 80 °C for 24 hours. The solution was diluted with CHCl<sub>3</sub> (100 ml) and the sieves were removed by filtration. The organic filtrate was washed with water (6 × 100 ml) and brine (100 ml), then dried with MgSO<sub>4</sub> and filtered. Solvent was removed *in vacuo* to leave a crude product. Purification by column chromatography through a silica plug resulted in a clear oil. (43 mg, 8 %); R<sub>f</sub> = 0.2 in 1: 4 EtOAc: 40-60° petroleum ether;  $v_{max}/cm^{-1}$  2925 (C-H), 2854 (C-H), 1737 (C=O), 1196 (C-O), 1108 (C-O), 765, 692; <sup>1</sup>H

NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.70 – 7.69 (m, 2H, H<sup>5</sup>), 7.42– 7.41 (m, 3H, H<sup>6/7</sup>), 4.50 – 4.45 (m, 1H, H<sup>1</sup>), 4.45 – 4.40 (m, 1H, H<sup>1</sup>), 3.69 – 3.63 (m, 3H, H<sup>a</sup>), 3.43 – 3.38 (m, 1H, H<sup>2</sup>), 3.27 – 3.23 (m, 1H, H<sup>2</sup>), 2.35 – 2.21 (m, 2H, H<sup>c</sup>), 1.89 – 1.59 (m, 2H, H<sup>d</sup>), 1.58 – 1.10 (m, 24H, H<sup>e-i,j-p</sup>), 0.98 – 0.72 (m, 3H, H<sup>q</sup>); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  174.45 (C<sup>b</sup>), 174.38 (C<sup>b</sup>), 162.29 (C<sup>3</sup>), 162.23 (C<sup>3</sup>), 159.36 (C<sup>3</sup>), 159.28 (C<sup>3</sup>), 130.04 (C<sup>4</sup>), 129.95 (C<sup>7</sup>), 129.84 (C<sup>7</sup>), 129.52 (C<sup>4</sup>), 128.89 (C<sup>6</sup>), 128.86 (C<sup>6</sup>), 127.12 (C<sup>5</sup>), 127.02 (C<sup>5</sup>), 86.65 (C<sup>1</sup>), 86.60 (C<sup>1</sup>), 85.52 (C<sup>1</sup>), 85.46 (C<sup>1</sup>), 52.69 (C<sup>2</sup>), 52.63 (C<sup>2</sup>), 51.61 (C<sup>a</sup>), 48.47 (C<sup>2</sup>), 48.39 (C<sup>2</sup>), 35.55 (C<sup>c</sup>), 34.29 – 22.57 (C<sup>d-i/j-o</sup>), 14.28 – 14.21 (C<sup>q</sup>); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>26</sub>H<sub>41</sub>NO<sub>3</sub> + Na<sup>+</sup>): 438.2979, found: 438.2977 (M + Na<sup>+</sup>).

#### 1.10 General procedure for the synthesis of oligomers O<sup>1</sup>3, O<sup>1</sup>5a, O<sup>2</sup>5a and O<sup>1</sup>5c(S) Stearic

Compound **1a** (1 eq.) was dissolved in DMF (0.5 M) followed by dipolarophile (8 eq.) and 4 Å MS (1600 g / mol of **1a**), the mixture was then raised to 80 °C for 24 hours. The solution was diluted with CHCl<sub>3</sub> (100 ml) and the sieves were removed by filtration. The organic filtrate was washed with water (6 × 100 ml) and brine (100 ml), then dried with MgSO<sub>4</sub> and solvent removed *in vacuo*, to leave a crude mixture of repeat units and dipolarophile. The crude product was separated by column chromatography, initially running in 100 % EtOAc to recover residual dipolarophile followed by 20 % acetone in EtOAc then 50 % acetone in EtOAc to recover the oligomers separately.

1.10.1 O<sup>1</sup>3-ABA oligomer (3-1a-3)




Orange waxy oil, (53 %); Rf = 0.55 in 100 % EtOAc;  $v_{max}$  / cm<sup>-1</sup>: 3289 (C=C–H), 3241 (C=C–H), 2925 (C-H), 2854 (C-H), 2118 (C=C), 1647 (C=O), 1407 (C-N), 912 (C-H); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (m, 1H, H<sup>6</sup>), 7.91 – 7.86 (m, 2H, H<sup>7</sup>), 7.59 – 7.50 (m, 1H, H<sup>8</sup>), 6.61 (s, 2H, H<sup>3</sup>-min), 6.60 (s, 2H, H<sup>3</sup>-maj), 4.82 (s, 4H, H<sup>1</sup>),

4.35 (d, J = 2.0 Hz, 4H, H<sup>1'</sup>-min), 4.18 (s, 4H, H<sup>1'</sup>-maj), 2.36 (t, J = 2.0 Hz, 2H, H<sup>3'</sup>-maj), 2.29 (t, J = 2.0 Hz, 2H, H<sup>3'</sup>-maj), 2.27 (s, 6H, H<sup>b</sup>-min), 2.25 (s, 6H, H<sup>b</sup>-maj); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  170.62 (C<sup>a</sup>-maj), 170.22 (C<sup>a</sup>-min), 169.31 (C<sup>2</sup>-min), 169.22 (C<sup>2</sup>-maj), 168.59 (C<sup>2</sup>-min), 168.47 (C<sup>2</sup>-maj), 162.19 (C<sup>4</sup>-maj), 162.11 (C<sup>4</sup>-min), 129.93 (C<sup>5</sup>-min), 129.87 (C<sup>8</sup>-maj), 129.79 (C<sup>5</sup>-maj), 129.76 (C<sup>8</sup>-min), 129.54 (C<sup>5</sup>-min), 129.40 (C<sup>5</sup>-maj), 128.70 (C<sup>7</sup>-min), 128.41 (C<sup>7</sup>-maj), 125.36 (C<sup>6</sup>-min), 125.33 (C<sup>6</sup>-maj), 101.47 (C<sup>3</sup>-maj), 101.17 (C<sup>3</sup>-min), 101.14 (C<sup>3</sup>-min), 78.25 (C<sup>2'</sup>-min), 77.54 (C<sup>2'</sup>-min), 73.70 (C<sup>3'</sup>-maj), 73.25 (C<sup>3'</sup>-min),

43.37 (C<sup>1</sup>-min), 40.80 (C<sup>1</sup>-maj), 38.85 (C<sup>1'</sup>-maj), 38.81 (C<sup>1'</sup>-maj), 34.62 (C<sup>1'</sup>-min), 21.72 (C<sup>b</sup>-min), 21.59 (C<sup>b</sup>-maj); *m/z*: (ES<sup>+</sup>) calcd. (C<sub>24</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub> + Na<sup>+</sup>): 453.1533, found: 453.1531 (M + Na<sup>+</sup>).


1.10.2 O<sup>1</sup>5a-ABA oligomer (5a-1a-5a)



Oil (75 %); Rf = 0.20 in 100 % EtOAc;  $v_{max}$ / cm<sup>-1</sup>: 3286 (C=C–H), 2922 (C-H), 2854 (C-H), 2114 (C=C), 1630 (C=O), 1435 (C-N), 1098 (C-O), 910 (C-H); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.49 (d, J = 3.5 Hz, H<sub>4,5-isoxazole</sub>), 8.22 (s, 1H, H<sub>8</sub>), 7.93 – 7.87 (m,


2H, H<sub>9</sub>), 7.59 – 7.53 (m, 1H, H<sub>10</sub>), 6.64 (s, 2H, H<sub>5</sub>), 6.63 (s, 2H, H<sub>5</sub>), 6.62 (s, 2H, H<sub>5</sub>), 6.61 (s, 2H, H<sub>5</sub>), 4.67 (s, 4H, H<sub>3</sub>-min), 4.64 (s, 4H, H<sub>3</sub>-maj), 4.14 (d, J = 2.5 Hz, 4H, H<sub>3</sub>'-maj), 4.12 (d, J = 2.5 Hz, 4H, H<sub>3</sub>'-min), 3.74 (dt, J = 10.5, 5.5 Hz, 4H, H<sub>2</sub>), 3.67 (dt, J = 14.5, 4.5 Hz, 8H, H<sub>2</sub>'), 3.64 – 3.56 (m, 8H, H<sub>1/1</sub>'), 2.43 (t, J = 2.5 Hz, H<sub>5</sub>'-maj), 2.41 (t, J = 2.5 Hz, H<sub>5</sub>'-min), 2.16 (s, H<sub>b</sub>-min), 2.13 (s, H<sub>b</sub>-maj); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  171.47 (C<sub>a</sub>-maj), 171.43 (C<sub>a</sub>), 170.02 (C<sub>3</sub>-maj), 169.92 (C<sub>3</sub>), 162.04 (C<sub>6</sub>), 161.95 (C<sub>6</sub>-maj), 129.88 (C<sub>7</sub>), 129.85 (C<sub>7</sub>), 129.84 (C<sub>10</sub>-min), 129.81 (C<sub>10</sub>-maj), 129.77 (C<sub>10</sub>-min), 129.75 (C<sub>7</sub>), 128.49 (C<sub>9</sub>), 128.45 (C<sub>9</sub>), 125.37 (C<sub>8</sub>), 101.33 (C<sub>5</sub>), 101.30 (C<sub>5</sub>), 101.23 (C<sub>5</sub>), 101.21 (C<sub>5</sub>), 79.69 (C<sub>4'</sub>-min), 79.37 (C<sub>4'</sub>-maj), 75.01 (C<sub>5'</sub>-maj), 74.68 (C<sub>5'</sub>-maj), 58.63 (C<sub>3'</sub>-maj), 69.44 (C<sub>3'</sub>-min), 68.90 (C<sub>2'</sub>-min), 68.07 (C<sub>2'</sub>-maj), 64.30 (C<sub>3</sub>-min), 64.00 (C<sub>3</sub>-maj), 58.63 (C<sub>3'</sub>-maj), 58.44 (C<sub>3'</sub>-min), 49.95 (C<sub>1/1'</sub>-maj), 49.91 (C<sub>1/1'</sub>-min), 46.45 (C<sub>1/1'</sub>-min), 46.43 (C<sub>1/1'</sub>-maj), 21.98 (C<sub>b</sub>-maj); m/z: (ES<sup>+</sup>) calcd. (C<sub>32</sub>H<sub>38</sub>N<sub>4</sub>O<sub>8</sub> + Na<sup>+</sup>): 629.2582, found: 629.2578 (M + Na<sup>+</sup>).

1.10.3 O<sup>2</sup>5a-ABABA oligomer (5a-1a-5a-1a-5a)



Cream solid, (3 %); Rf = 0.1 in 20 % Ac in EtOAc; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.49 (d, *J* = 3.5 Hz, H<sub>4,5</sub>. isoxazoline), 8.21 (s, 2H, H<sup>8</sup>), 7.93 – 7.84 (m, 4H, H<sup>9/11</sup>), 7.54 (t, *J* = 7.5 Hz, 2H, H<sup>10</sup>), 6.66 – 6.58 (m, 4H, H<sup>5/14</sup>), 4.72 – 4.58 (m, 8H, H<sup>3/16</sup>), 4.14 (d, *J* = 2.5 Hz, 4H, H<sup>3'</sup>-maj), 4.11 (d, *J* = 2.5 Hz, 4H, H<sup>3'</sup>-min), 3.79 – 3.70 (m, 8H, H<sup>2/17</sup>), 3.70 – 3.55 (m, 16H, H<sup>1/18/1'/2'</sup>), 2.43 (t, *J* = 2.5 Hz, 2H, H<sup>5'</sup>-maj), 2.41 (t, *J* = 2.5 Hz, 2H, H<sup>5'</sup>-min), 2.16 (s, 9H, H<sup>b/d</sup>-maj), 2.12 (s, 9H, H<sup>b/d</sup>-min); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  171.52 (C<sup>a/c</sup>), 171.49 (C<sup>a/c</sup>), 171.45 (C<sup>a/c</sup>), 170.02 (C<sup>5/14</sup>), 169.92 (C<sup>5/14</sup>), 169.89 (C<sup>5/14</sup>), 169.82 (C<sup>5/14</sup>), 162.01 (C<sup>6/13</sup>), 161.95 (C<sup>6/13</sup>), 161.93 (C<sup>6/13</sup>), 129.87 (C<sup>7/12</sup>), 129.85 (C<sup>7/12</sup>), 129.83 (C<sup>10</sup>), 129.80 (C<sup>10</sup>), 129.75 (C<sup>7/12</sup>), 129.72 (C<sup>7/12</sup>), 128.47 (C<sup>9/11</sup>), 128.43 (C<sup>9/11</sup>), 128.34 (C<sup>9/11</sup>), 125.34 (C<sup>8</sup>), 101.41 (C<sup>5/14</sup>), 101.39 (C<sup>5/14</sup>), 101.33 (C<sup>5/14</sup>), 101.23 (C<sup>5/14</sup>), 101.20 (C<sup>5/14</sup>), 79.70 (C<sup>4'</sup>), 79.38 (C<sup>4'</sup>), 75.02 (C<sup>5'</sup>-maj), 74.69 (C<sup>5'-min</sup>), 69.95 (C<sup>2/17/2'</sup>), 69.86 (C<sup>2/17/2'</sup>), 69.46 (C<sup>2/17/2'</sup>), 68.88 (C<sup>2/17/2'</sup>), 68.06 (C<sup>2/17/2'</sup>), 64.29 (C<sup>3/16</sup>), 64.23 (C<sup>3/16</sup>), 63.99 (C<sup>3/16</sup>), 63.95 (C<sup>3/16</sup>), 58.63 (C<sup>3'</sup>), 58.44 (C<sup>3'</sup>), 50.06 (C<sup>1/18/1'</sup>), 49.95 (C<sup>1/18/1'</sup>), 49.91 (C<sup>1/18/1'</sup>), 46.65 (C<sup>1/18/1'</sup>), 46.44 (C<sup>1/18/1'</sup>), 46.42 (C<sup>1/18/1'</sup>), 21.98 (C<sup>b/d</sup>-maj), 21.93 (C<sup>b/d</sup>-maj) ; MS (ESI) m/z calcd. (C<sub>52</sub>H<sub>59</sub>N<sub>7</sub>O<sub>13</sub> + Na<sup>+</sup>): 1012.4063, found: 1012.4067 (M + Na<sup>+</sup>).


1.10.4  $O^{1}5c(S)$ -ABA oligomer (5c(S)-1a-5c(S))




White waxy residue (48 %); Rf 0.1 in 50 % EtOAc; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.49 (s, H<sup>3,4-isoxazole</sup>), 8.25 – 8.21 (m, 1H, H<sup>8</sup>), 7.92 – 7.88 (m, 2H, H<sup>9</sup>), 7.59 – 7.53 (m, 1H, H<sup>10</sup>), 6.64 (s, 2H, H<sup>5</sup>), 6.63 (s, 2H, H<sup>5</sup>) 6.62 (s, 2H, H<sup>5</sup>) 4.67 (s, 2H, H<sup>3</sup>-min), 4.64 (s, 2H, H<sup>3</sup>-maj), 4.14 (d, *J* = 2.5 Hz, 2H, H<sup>3'-</sup>min), 4.12 (d, *J* = 2.5 Hz, 2H, H<sup>3'-</sup>min), 3.77 – 3.57 (m, 8H, H<sup>1/1'/2/2'</sup>), 2.43 (t, *J* = 2.5 Hz, 2H, H<sup>5'</sup>), 2.41 (t, *J* = 2.5 Hz, 2H, H<sup>5'</sup>), 2.40 – 2.33 (m, 2H, H<sup>b</sup>), 1.66 – 1.57 (m, 2H, H<sup>c</sup>), 1.34 – 1.18 (m, 56H, H<sup>d-q</sup>), 0.88 (t, *J* = 6.9 Hz, 6H, H<sup>r</sup>); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  173.98 (C<sup>a</sup>-maj), 173.93 (C<sup>a</sup>-min) 170.10 (C<sup>4</sup>-maj), 169.94 (C<sup>4</sup>-min), 162.02 (C<sup>6</sup>), 161.94 (C<sup>6</sup>), 129.93 (C<sup>7</sup>), 129.89 (C<sup>7</sup>), 129.83 (C<sup>10</sup>), 129.79 (C<sup>10</sup>), 129.76 (C<sup>10</sup>), 128.49 (C<sup>9</sup>), 128.45 (C<sup>9</sup>), 125.35 (C<sup>8</sup>), 101.27 (C<sup>5</sup>), 101.25 (C<sup>5</sup>), 101.23 (C<sup>5</sup>), 79.76 (C<sup>4'</sup>-maj), 79.40 (C<sup>4'-maj</sup>), 64.32 (C<sup>3</sup>-maj), 64.02 (C<sup>3</sup>-maj), 58.64 (C<sup>3'</sup>-maj), 58.44 (C<sup>3'</sup>-min), 49.02 (C<sup>1/1'</sup>-maj), 48.99 (C<sup>1/1'</sup>-min), 46.69 (C<sup>1/1'</sup>-min), 46.44 (C<sup>1/1'</sup>-maj), 33.32 (C<sup>b</sup>), 33.28 (C<sup>b</sup>), 32.07 (C<sup>p</sup>), 29.89 – 29.51 (C<sup>d-o</sup>), 25.49 (C<sup>c</sup>), 25.44 (C<sup>c</sup>), 22.84 (C<sup>q</sup>), 14.27 (C<sup>r</sup>); *m/z:* (ES<sup>+</sup>) calcd. (C<sub>64</sub>H<sub>102</sub>N<sub>4</sub>O<sub>8</sub> + Na<sup>+</sup>): 1077.7590, found: 1077.7590 (M + Na<sup>+</sup>).

## 2.0 NMR and VT NMR data for new compounds


## 2.1 N,N-di(prop-2-yn-1-yl)acetamide 3




## 2.2 *N,N*-bis(2-(prop-2-yn-1-yloxy)ethyl)acetamide 5a(Me)





## 2.3 *N,N-*bis(2-(prop-2-yn-1-yloxy)ethyl)palmitamide 5b(P)



## 2.4 *N,N-*bis(2-(prop-2-yn-1-yloxy)ethyl)stearamide 5c(S)










## 2.6 (9Z,12Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12-dienamide 5e(L)

#### 








## 2.7 (9Z,12Z,15Z)-N,N-bis(2-(prop-2-yn-1-yloxy)ethyl)octadeca-9,12,15-trienamide 5f(Ln)




2.8 Methyl-8-(4-octyl-3-phenyl-4,5-dihydroisoxazol-5-yl)octanoate and regioisomer 8a-d











## 2.10 O<sup>1</sup>5a(Me)-ABA














## 2.13 P(1a-co-5a(Me))




## 2.14 P(1a-co-5b(P)) Palimitic





## 2.15 P(1a-co-5c(S)) Stearic





## 2.16 P(1a-co-5d(O)) Oleic



















## 2.19 P<sub>base</sub>(1a-co-5a(S)) Stearic























#### 2.21 8a-d diastereomer and regioisomeric mixture






2.22 3,4-Diphenyl-1,2,5-oxadiazol-2-oxide 2




## 3.0 Variable Temperature NMR spectra

5a(Me)




#### 4.3 4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1. f1 (ppm)



# 5c(O) Oleic

<sup>4.190 4.185 4.180 4.175 4.170 4.165 4.160 4.155 4.150 4.145 4.140 4.135 4.130 4.125 4.120 4.115 4.110 4.105 4.100 4.095 4.090 4.085 4.080 4.075 4.070 4.065 4.060</sup> f1 (ppm)





8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 6.0 5.8 5.6 5.4 5.2 5.0 4.8 4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 2.1 fl (ppm)


### O<sup>1</sup>5a(Me)-ABA


| 373 K |          |  |
|-------|----------|--|
| 363 K |          |  |
| 353 K |          |  |
| 343 K |          |  |
| 333 K |          |  |
| 323 K |          |  |
| 313 K |          |  |
| 202 K | $\wedge$ |  |
| 303 K |          |  |

|       | O <sup>1</sup> 5c(S)-ABA Stearic |
|-------|----------------------------------|
| 373 K |                                  |
| 363 K |                                  |
| 353 K |                                  |
| 343 K |                                  |
| 333 K |                                  |
| 323 K |                                  |
| 313 K |                                  |
| 303 K |                                  |
| 298 K |                                  |
| 293 K |                                  |


4.83 4.82 4.81 4.80 4.79 4.78 4.77 4.76 4.75 4.74 4.73 4.72 4.71 4.70 4.69 4.68 4.67 4.66 4.65 4.64 4.63 4.62 4.61 4.60 4.59 4.58 4.57 4.56 4.55 4.54 4.53 4.52 4.51 f1 (ppm)

# 4.0 Infrared spectra







N,N-di(prop-2-yn-1-yl)acetamide 3




O<sup>1</sup>3 oligomer ABA


Wavenumber cm-1






P(1a-co-5b(P)) Palmitic








P(1a-co-5c(S)) Stearic




P(1a-co-5e(L)) Linoleic









Pbase(1b-co-5c(S)) Stearic (para nitrile-N-oxide)






### 5.0 MALDI-TOF mass spectra for selected polymers







Calibration



P(1a-co-5a(Me))



### 6.0 DMA data P<sub>base</sub>(1a-co-5c(S)) and P<sub>base</sub>(1b-co-5c(S)) Stearic.




### 7.0 Experimental data for screening of base-mediated polymerisations.

All polymerisations were carried out at room temperature for 24 hours with 1:1 stoichiometry of **5c(S)** and **1a** unless highlighted by an asterisk in which case the stoichiometry was 1.0:1.1 **5c(S):1a**. All GPC's were carried out in THF as eluent and PMMA as a calibration standard.

| Entry | Conditions                            | Solvent           | Conversion | Mn    | Mw    | Ð   |
|-------|---------------------------------------|-------------------|------------|-------|-------|-----|
| 1     | Cul, K <sub>2</sub> CO <sub>3</sub>   | Et <sub>2</sub> O | 77%        | 5.4K  | 6.6K  | 1.2 |
| 2     | Cul, K <sub>2</sub> CO <sub>3</sub>   | DMF               | 57%        | 0.8K  | 1.9K  | 1.7 |
| 3     | Cul, K₂CO₃                            | acetone           | 59%        | 1.0K  | 2.2K  | 1.8 |
| 4     | Cul, K <sub>2</sub> CO <sub>3</sub> * | $Et_2O$           | 80%        | 3.5K  | 7.3K  | 2.1 |
| 5     | Cul, K₂CO₃                            | CHCl₃             | 70%        | 1.9K  | 2.1K  | 1.1 |
| 6     | Cul, Et₃N                             | CHCl₃             | 75%        | 3.4K  | 3.9K  | 1.1 |
| 7     | NaHCO <sub>3</sub>                    | EtOAc             | 77%        | 3.3K  | 3.4K  | 1.0 |
| 8     | Na <sub>2</sub> CO <sub>3</sub>       | DCM               | 85%        | 5.5K  | 7.7K  | 1.3 |
| 9     | Na <sub>2</sub> CO <sub>3</sub>       | DMF               | 55%        | 1.8K  | 2.0K  | 1.0 |
| 10    | Na <sub>2</sub> CO <sub>3</sub>       | acetone           | 70%        | 1.9K  | 2.0K  | 1.0 |
| 11    | K <sub>2</sub> CO <sub>3</sub>        | $Et_2O$           | 89%        | 6.7K  | 9.1K  | 1.8 |
| 12    | K <sub>2</sub> CO <sub>3</sub>        | acetone           | 66%        | 2.2K  | 3.0K  | 1.3 |
| 13    | K <sub>2</sub> CO <sub>3</sub>        | THF               | 86%        | 4.8K  | 6.8K  | 1.8 |
| 14    | K <sub>2</sub> CO <sub>3</sub>        | EtOH              | 94%        | 18.5K | 35.5K | 1.9 |
| 15    | $K_2CO_3^*$                           | EtOH              | 96%        | 19.0K | 36.2K | 1.9 |


### 8.0 GPC data of entries 1-15 from section 8.0

All GPC was carried out in THF using a PMMA calibration standard.





| Polymer  |    | Mp <sup>a</sup> (kDa) |     |      |     |     |
|----------|----|-----------------------|-----|------|-----|-----|
|          |    |                       |     | Peak |     |     |
|          |    | 1                     | 2   | 3    | 4   | 5   |
| Reaction | 1  | 0.3                   | 1.0 | 2.3  | 3.7 | 4.5 |
| time     | 2  | 0.3                   | 1.0 | 2.4  | 3.7 | 4.5 |
|          | 3  | 0.3                   | 1.0 | 2.3  | 3.6 | 4.8 |
|          | 6  | 0.3                   | 1.0 | 2.5  | 3.9 | 5.0 |
|          | 24 | 0.3                   | 1.0 | 2.5  | 3.9 | 5.2 |
|          | 72 | 0.3                   | 0.9 | 2.3  | 3.7 | 4.9 |

GPC data for polymers showing the peak molecular weight (Mp) <sup>a</sup>Determined by GPC analysis in THF, calibrated against PMMA standards.




GPC analysis of peak maximum (Mp) in polymerisation samples of entry 4. <sup>a</sup>GPC analysis was conducted in THF using PMMA as a calibration standard





### 9.0 Thermal Gravimetric Analysis of all polymers and ABA type oligomers

TGA was achieved using a Mettler-Toledo TGA or a TA Instruments Discovery SDT 650 with autosampler. TGA samples, under nitrogen, were heated from 25 °C – 600 °C at 10 °C / min in 40  $\mu$ l aluminium pans.



### 10.0 References

- 1. Koyama, Y.; Yonekawa, M.; Takata, T. *Chem. Lett.* **2008**, *37* (9), 918–919.
- 2. Kelly, D. R.; Baker, S. C.; King, D. S.; de Silva, D. S.; Lord, G.; Taylor, J. P. *Org. Biomol. Chem.* **2008**, 6 (4), 787–796.
- 3. Aitken, R. A.; Smith, M. H.; Wilson, H. S. J. Mol. Struct. **2016**, *1113*, 171–173.
- Guan, L. P.; Sui, X.; Deng, X. Q.; Zhao, D. H.; Qu, Y. Le; Quan, Z. S. *Med. Chem. Res.* 2011, 20 (5), 601–606.
- 5. Sagnella, S. M.; Conn, C. E.; Krodkiewska, I.; Drummond, C. J. *Phys. Chem. Chem. Phys.* **2011**, *13*, 13370–13381.